|
1) Mason DA, Moore JD, Green SA, et al. A gain-of-function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor. J Biol Chem. 1999; 274: 12670-4
|
|
|
|
2) Mialet-Perez J, Rathz DA, Petrashevskaya NN, et al. β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003; 9: 1300-5
|
|
|
|
|
|
3) Green SA, Cole G, Jacinto M, et al. A polymor-phism of the human β2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem. 1993; 268: 23116-21
|
|
|
|
|
|
4) Turki J, Lorenz JN, Green SA, et al. Myocardial signaling defects and impaired cardiac function of a human β2-adrenergic receptor polymor-phism expressed in transgenic mice. Proc Natl Acad Sci U S A. 1996; 93: 10483-8
|
|
|
|
|
|
5) Small KM, Forbes SL, Rahman FF, et al. A four amino acid deletion polymorphism in the third intracellular loop of the human α2c-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem. 2000; 275: 23059-64
|
|
|
|
|
|
6) Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure. Nat Med. 2008; 14: 510-7
|
|
|
|
|
|
7) Small KM, Wagoner LE, Levin AM, et al. Syner-gistic polymorphisms of β1- and α2c-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 2002; 347: 1135-42
|
|
|
|
|
|
8) Nonen S, Okamoto H, Akino M, et al. No positive association between adrenergic receptor variants of alpha2cDel322-325, beta1Ser49, beta1Arg389 and the risk for heart failure in the Japanese population. Br J Clin Pharmacol. 2005; 60: 414-7
|
|
|
|
|
|
9) Regitz-Zagrosek V, Hocher B, Bettmann M, et al. Alpha2C-adrenoceptor polymorphism is associ-ated with improved event-free survival in pa-tients with dilated cardiomyopathy. Eur Heart J. 2006; 27: 454-9
|
|
|
|
|
|
10) Wagoner LE, Craft LL, Singh B, et al. Polymor-phisms of the β2-adrenergic receptor determine exercise capacity in patients with heart failure. Circulation. 2000; 86: 834-40
|
|
|
|
|
|
11) Liggett SB, Wagoner LE, Craft LL, et al. The Ile164β2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest. 1998; 102: 1534-9
|
|
|
|
|
|
12) Beta-Blocker Evaluation of Survival Trial Inves-tigators: A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001; 344: 1659-67
|
|
|
|
|
|
13) Liggett SB, Mialet-Perez J, Theneemit-Chen S, et al. A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006; 103: 11288-93
|
|
|
|
|
|
14) Rochais F, Vilardaga J, Nikolaev VO, et al. Real-time optical recording of β1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest. 2007; 117: 229-35
|
|
|
|
|
|
15) De Groote P, Helbecque N, Lamblin N, et al. As-sociation between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable conges-tive heart failure. Pharmacogenet Genomics. 2005; 15: 137-42
|
|
|
|
|
|
16) Lobmeyer MT, Gong Y, Terra SG, et al. Syner-gistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics. 2007; 17: 277-82
|
|
|
|
|
|
17) Nonen S, Okamoto H, Fujio Y, et al. Polymor-phisms of norepinephrine transporter and adren-ergic receptor alpha1D are associated with the response to beta-blockers in dilated cardio-myopathy. Pharmacogenomics J. 2008; 8: 78-84
|
|
|
|
|
|
18) Terra SG, Hamilton KK, Pauly DF, et al. β1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to β-blocker therapy. Pharmacogenet Genomics. 2005; 15: 227-34
|
|
|
|
|
|
19) Chen L, Myers D, Javorsky G, et al. Arg389Gly-beta1-adrenergic receptors determine improve-ment in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet Genomics. 2007; 17: 941-9
|
|
|
|
|
|
20) de Groote P, Helbecque N, Lamblin N, et al. Association between beta-1 and beta-2 adren-ergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics. 2005; 15: 137-42
|
|
|
|
|
|
21) Kaye DM, Smirk B, Williams C, et al. β-Adren-oceptor genotype influences the response to carvedilol in the patients with congestive heart failure. Pharmacogenetics. 2003; 13: 379-82
|
|
|
|
|